Trial reportJournal of the American Society of Nephrology : JASN2013
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.
Trial report in Journal of the American Society of Nephrology : JASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans.Physiological reports · 2017Trial
- Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.European journal of preventive cardiology · 2016Trial
- Novel protein biomarkers for risk stratification and personalized medicine.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- The role of endothelin receptor antagonists in kidney disease.Renal failure · 2025Review
- The Role of Endothelin-1, Kidney Function and Diabetes in Patients With Coronary Artery Disease Underwent Percutaneous Coronary Intervention.Journal of diabetes · 2025Article
- Endothelin receptor antagonists in chronic kidney disease.Nature reviews. Nephrology · 2025Review
- Specificity of endothelial cells in endothelial dysfunction of diabetic kidney disease and their crosstalk with neighboring cells: an updated review.Frontiers in endocrinology · 2025Review
- Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.American journal of physiology. Renal physiology · 2024Article
- Endothelin system expression in the kidney following cisplatin-induced acute kidney injury in male and female mice.Canadian journal of physiology and pharmacology · 2022Article
- Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease.iScience · 2021Article
- Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy.Journal of clinical medicine · 2020Review
- Endothelins in cardiovascular biology and therapeutics.Nature reviews. Cardiology · 2019Review
- Review
- Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Toxins · 2018Review
- Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.Hypertension (Dallas, Tex. : 1979) · 2017Review
- Arterial stiffness &Sri Lankan chronic kidney disease of unknown origin.Scientific reports · 2016Article
- Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.American journal of nephrology · 2016Article
- Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.Journal of the American Society of Nephrology : JASN · 2015Article
- Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Article
- Endothelin receptors and their antagonists.Seminars in nephrology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Arterial stiffness and impaired nitric oxide (NO) bioavailability contribute to the high risk for cardiovascular disease in CKD. Both asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting that ET-1 receptor antagonists may have a role in cardiovascular protection in CKD. We conducted a randomized, double-blind, three-way crossover study in 27 patients with proteinuric CKD to compare the effects of the ET(A) receptor antagonist sitaxentan, nifedipine, and placebo on proteinuria, BP, arterial stiffness, and various cardiovascular biomarkers. After 6 weeks of treatment, placebo and nifedipine did not affect plasma urate, ADMA, or urine ET-1/creatinine, which reflects renal ET-1 production; in contrast, sitaxentan led to statistically significant reductions in all three of these biomarkers. No treatment affected plasma ET-1. Reductions in proteinuria and BP after sitaxentan treatment was associated with increases in urine ET-1/creatinine, whereas reduction in pulse-wave velocity, a measure of arterial stiffness, was associated with a decrease in ADMA. Taken together, these data suggest that ET(A) receptor antagonism may modify risk factors for cardiovascular disease in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.